Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873838 | 0.94 | EPHX2 (0.62) | EPHX2CYP2C9PRMT5WDR77HRH3 | |
| SCHEMBL13873662 | 0.93 | EPHX2 (0.62) | EPHX2CYP2C9PRMT5WDR77NAMPT | |
| SCHEMBL13873666 | 0.93 | EPHX2 (0.64) | EPHX2CYP2C9PRMT5WDR77NAMPT | |
| SCHEMBL13873664 | 0.88 | CYP2C9 (0.61) | EPHX2CYP2C9PRMT5WDR77NAMPT | |
| SCHEMBL13873832 | 0.87 | CYP2C9 (0.58) | EPHX2CYP2C9PRMT5WDR77KDM4E | |
| SCHEMBL13873665 | 0.85 | EPHX2 (0.54) | EPHX2CYP2C9PRMT5WDR77NAMPT | |
| SCHEMBL13873660 | 0.83 | CYP2C9 (0.56) | EPHX2CYP2C9NAMPTKDM4EEPHX1 | |
| SCHEMBL13873671 | 0.82 | CYP2C9 (0.57) | EPHX2CYP2C9PRMT5WDR77HRH3 | |
| SCHEMBL13873834 | 0.81 | EPHX2 (0.58) | EPHX2CYP2C9PRMT5WDR77MEN1 | |
| SCHEMBL13873835 | 0.81 | EPHX2 (0.63) | EPHX2CYP2C9PRMT5WDR77NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C9 477/4885PRMT5 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.